business the company, I and Tony. And the results current XXXX. good granularity key begin Thank for first-quarter you, high-level of areas focus for afternoon, will environment on additional some the around our everyone. of comments with and rest provide then
-release period of rapid company. As our on XXst, a in been change we April indicated our QX pre for has
like remain the innovation and in Board we're corporate decades thank of of Mike Directors. On years. his welcome Board. past experience as Chairman health technologies, Irish Timothy director would along Klein, Board of insight announced to team, of excited leadership our the offers He who proven tremendous the the the and Board track strategic Michael as And we of As of management over he I Directors of for three Norris of change. appointment relevant with will entire contributions of as succeed will a behalf and as leading to the the and Tim record Chairman
recently an company. also the his in to will leaving on Charles assist also that and over as appreciate place. entire for with future CFO the would personal behalf be will company the Financial as period important transition thank company's role for of Chief the Charlie Board Carter, that played Officer, reasons. I We success. his serve his for a until work of Charlie the of our the of is past successor announced our continue like CFO the Directors to to team responsibilities during He support contributions has iCAD we year. And transition
opportunities our the right we has are point been treatment heights. believe business. solutions the brain Based team have to robust the QX, for I what expanding to existing the ways technologies vision the our believe technologies to flexible With continue broader therapy the in strength portfolio that the differentiated beyond shared the applications laying in successfully of and portfolio, technologies continued Xoft previously access success to market as promising accomplished segment, an new of aggressively segment, offers detection We solutions large our in path to leverage sides targeting under-penetrated potential that in and across company and our tumors powerful customer plan this by both more such to important needs. that foundation offering of team a XXXX our we strategic place a right in elevate and the cancer robust plans team of year. in we in meet in for execute markets portfolio and the to our on and expansion world-leading the inflection have We significant at currently of our of
to global environment we in resulted to open From COVID QX, positive and beginning environment business Although proactively a took continued up beginning supply QX, for the We as areas in EU more side to positive earlier This more many cross-border a many potential of present starting activities access the pandemic ease. to are last return perspective, as into began the number traditional in once year to progress chain to part -related supply challenges the restrictions in better a normal a And to continuing has, saw travel, globe. such thankfully began again. COVID and are the reduce as loosen restrictions in around we particularly cases of to customer steps, disruption. decision-makers.
potential rest While the inflationary this may to resulted to that year. it increases, cash higher-than-anticipated prudent we against cushion shortages establish and price burn, believe come short-term we inventory of component disruption any in to was protect believe well-positioned we're an weather the now and
previously XXXX. in laser-focus for for would express XXXX, a iCAD's and solid a dedicated foundation particularly look my on laid to out, closer in XXXX, less execution on to build the fact continued in we sincere like provide we developed hard at scenarios ultimately and is range Taking This for success. long-term results early results. the the allow total track with Overall, expected our simultaneously have our quarter, QX, and that gratitude company subsequent and these a to commercial COVID teams million. cash the in conserve to forward Moving that in and $X.XX given result trajectory for burn encouraging and a and position cash plans achieving revenue to of generate I plan QX should was we their we substantially quarters, us to infrastructure overhauling is headwinds the working were our
emerging needs customers. key Looking at our of address aspects enterprise-level the market the better to are our of penetration available the the plan, of to increase Detection business, broader and the
successful the became clear skills it However, forward. we emphasized to different that both initiatives approaches in enabling skills And not the moving the were that we sales early success, be and require have our past. skills needed than same what
worked a diligently we and our great across our sales U.S. new progress successful key with have made in motion the As and sales enhancing territories have adjust highly personnel commercial result, infrastructure to in
and for recent, these already Although initiatives iCAD pipeline. continually powered are our suite provider broader customers our market. workflow parallel, positive breast to positive they having With solutions. Solutions AI Breast announced momentum compared implemented in momentum superiority of recently leading goal ProFound We drive have to further our And AI a XD we particularly continuing changes clinical several continued mammography Health to we growing with customers are AI of QX, available systems. saw impact report In with penetrate the on ongoing in advantages a positive equipped among other to business.
Webinar AI, the Some using ProFound run year. impact of these customers our insights, their share been profound ProFound and which recently have new rest will launched experiences and and we Series, we'll of the through
sales skill a element proving customers. relationships to As to that new are expected, our is and key be sets with force us successfully enabling reach
across and several one an country research throughout For world U.S., example, well locations facilities other enterprise team as contracts key with renowned institutions worldwide. high-profile of deal largest the the the with QX, multiple in academic as with our solidified
accomplish the we forward. moving We are seeing, and with pleased we're excited success early by can what
needs important becoming aspect enterprise of Another leveraged installations and of address customers customers have and skill the larger evolved approach our better our commercial partnership represent very increased These a who in of we market. attractive generally traction the with longer-term to is our key the We're customers are team. as level are opportunity enhanced sales opportunities. very seeing they strategic plan with these detection sets
to Our now include include working our strategic procure our with QX. various to partnership aggregators. were our overall in of partners revenue to these to providing includes ways plan flexible see PACS customers vendors, also These legacy AI We technology. efforts some pleased expanding more and contribute
some on call, the decision the the for began budget Historically, model we learned approach testing due we last a but in to an some mentioned customers for the has to a prefer of plan. is long-term and begins operational constraints. that when license recurring budget QX also capital more a segment The business subscription will that been we purchasing software subscription who may investment a detection revenue ability and capital the model install technology our have payment base build to our customers flexible available, expense perpetual prefer the the customers generate in acquire not purchase, company. model allows As believe
personalized these including still we Congress the continue this not short-term look technology, small the it this expect in to edge breast We the product. of for this XXXX, in should which Belgium While a will The to a clinical place our risk grow percentage International research month, evidence Vienna overall QX, studies also on care only and making later we continues data to this and as that and for place take presented in be at growing from potential assessment We Risk the believe supporting to the July. screening, of to great ProFound customer is We're capital AI model. upcoming women. landscape currently technology to underway. of leading of take which strides model, European lead also this four tradeshows standard there revenue will with that first-in-kind we interest continue additional some our Radiology, in Workshop Imaging, has of cancer collect change Breast support with forward portfolio studies become to seeing of
we the we AI breast use working proud are a more of compelling we clinicians improve have technology, for even will to the this screening of that While data of to outcomes. cancer clinical report number additional growing ProFound make early Risk that adopters expect
help all together and technologies a a this In model, can bundled be our of that pricing as forward, premium pricing of package. including various drive adopted combinations exploring we are where could addition, adoption capability breast moving product AI
resources and the in restructuring to to fashion, to positioning derm a fell We our of driver Now, expect more this in U.S. XXXX. in primarily on accelerated presently for partners Revenue the including Xoft expect segment opportunity a to who end. go considerably additional be in of the QX, of due one growth our after continue therapy business. turning rebound dermatology expectations to is adding to sales their therapy business dermatology fully itself segment short our our primary
in in skin Derma first partner, We Florida for the and several more System in are this key Xoft our months our convert customers in Therapies installing with expect new QX to ahead. currently market
this RT, have more relationship. our on-boarded DermaCure of partner, expect also west several see successfully in result QX to strategic We placements coast a as and key
and were With QX in events shows planned pipeline restrictions that the happy that conferences this of geographic many look areas growing locations, I'm prospects. forward we in earlier stimulated able in-person QX to to have report to COVID we already trade momentum. various continuing in multiple in With to year, beginning lift dermatology attend more are this
examining and to Xoft and we advance to have radiation trial, least -operative intra Xoft expect of patients continue John's, have with Brain protocol by now the the U.S.. treated glioblastoma. for to date Additionally, new GLIOX the System we in treatment patients clinical end GLIOX of the concurrently Researchers with under QX, multiple at at five adding IORT multinational study the recurrent treated therapy use Providence the global while markets. St. ten sites both of our
Xoft glioblastoma reduce Spain head University multiple with ultimately indications practical optimize eBx doctors This of have GLIOX also the recurrent system the We're recently, treat for trial. facility potential which cancer, as with to example, For patients Xoft facilities, treatment the at used beginning effects, it preparation system see and new brain in that successfully enhances more to for cases Caceres, adding side neck in a rectal Xoft to has Caceres solution metastases, patient treated also and care. offers encouraged provides times and with tumors.
Spain University interest for Zaragoza, Notably, brain breast Servet the also We're Taiwan facility regimen for gynecological the clinicians more now than global in Xoft IORT years, to a metastases. XXX recently cancers of see Xoft in utilized breast gynecological for have sale example, cancer and in Miguel the markets cancers Xoft and sarcomas has system treatment and this their For other at treatment treated Hospital using QX. forward and XXX in momentum continuing in significant today. with been with cancers in
COVID the subscription earlier, improvement a in can to business, a our looking part the as environment, in pricing Now continue especially international be noted the we in AI and selling alternative. in see reduction introduction to attributed EU. This at restrictions of
We of portfolio portfolio of to the more was successfully of expect remain into this world-leading revenue optimistic believe our COVID We our geography changes technologies We unique European And the to contribute hard are our innovative clinicians ahead, remain navigating the are solutions a pipeline and business a where I the years value confident we case look in very organization hands more of to and and now ensure on beyond. as worldwide. I Charlie? the through have growing the been than necessary the XXXX to believe past two bring offers. we more opportunity by now that, walk continue to the to drive call capture will growth Charlie as you hit the to turn constraints. the in through financial from has solid highlights we infrastructure quarter. will that and and continue we trajectory over commercial place With we success stronger in for position
